Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 4

Results For "Chairman"

819 News Found

Zota Health Care expands Davaindia network to 1,530 stores
Healthcare | March 20, 2025

Zota Health Care expands Davaindia network to 1,530 stores

The company has also launched its first three 24*7 pharmacy stores via COCO model in Bengaluru


Aster DM Healthcare promoters reduce share pledge from 99% to 41%
News | March 12, 2025

Aster DM Healthcare promoters reduce share pledge from 99% to 41%

The new lenders – JP Morgan, HSBC, and Barclays provided fresh funding


Zota Health Care launched B2C online portal ‘davaindia’
Healthcare | March 11, 2025

Zota Health Care launched B2C online portal ‘davaindia’

This e-commerce platform is launched as a hyperlocal model


Sun Pharma to acquire Nasdaq-listed Checkpoint Therapeutics
News | March 10, 2025

Sun Pharma to acquire Nasdaq-listed Checkpoint Therapeutics

Will add UNLOXCYT (cosibelimab-ipdl), the first and only FDA-approved anti-PD-L1 treatment for metastatic or locally advanced cutaneous squamous cell carcinoma (cSCC) to Sun Pharma's global onco-derm franchise


Need for enhancing capacity building of medical officers to achieve desired results of healthcare schemes at the grassroot level: J. P. Nadda
Policy | March 05, 2025

Need for enhancing capacity building of medical officers to achieve desired results of healthcare schemes at the grassroot level: J. P. Nadda

Nadda also commended the role of ASHA workers, “grassroot foot soldiers”, in the healthcare system


Cupid receives Rs. 42 crore order from Tanzania
News | February 28, 2025

Cupid receives Rs. 42 crore order from Tanzania

We have big plans across our B2C and B2B businesses in India and abroad


Venus Remedies secures in-licensing rights from Infex Therapeutics to develop and commercialize MET-X in India
News | February 27, 2025

Venus Remedies secures in-licensing rights from Infex Therapeutics to develop and commercialize MET-X in India

MET-X, a novel metallo-beta-lactamase (MBL) inhibitor, has shown best-in-class performance in preclinical studies


Amgen opens new technology and innovation site in Hyderabad
Digitisation | February 25, 2025

Amgen opens new technology and innovation site in Hyderabad

Amgen India investment totals $200 million through 2025